SELLAS Life Sciences Group (NASDAQ:SLS) Stock Sees Heavy Put Option Buying

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the recipient of some unusual options trading activity on Monday. Stock traders bought 48,643 put options on the stock. This is an increase of 19% compared to the typical daily volume of 40,961 put options.

SELLAS Life Sciences Group Trading Down 4.2%

Shares of SLS traded down $0.33 during trading hours on Monday, reaching $7.53. The stock had a trading volume of 3,178,609 shares, compared to its average volume of 7,843,897. The firm has a 50-day simple moving average of $11.03 and a 200 day simple moving average of $8.77. SELLAS Life Sciences Group has a 12 month low of $1.39 and a 12 month high of $15.88. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -38.10 and a beta of 2.73.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05).

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SELLAS Life Sciences Group has a consensus rating of “Hold” and a consensus price target of $10.00.

Check Out Our Latest Analysis on SLS

Institutional Trading of SELLAS Life Sciences Group

A number of large investors have recently modified their holdings of the business. Nykredit A S bought a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at $27,000. GAMMA Investing LLC lifted its stake in SELLAS Life Sciences Group by 293.2% in the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock worth $27,000 after purchasing an additional 1,630 shares during the last quarter. Sterling Capital Management LLC lifted its stake in SELLAS Life Sciences Group by 900.8% in the third quarter. Sterling Capital Management LLC now owns 6,635 shares of the company’s stock worth $82,000 after purchasing an additional 5,972 shares during the last quarter. City State Bank bought a new stake in SELLAS Life Sciences Group in the third quarter worth $100,000. Finally, California State Teachers Retirement System boosted its position in SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after buying an additional 1,709 shares during the period. Institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

(Get Free Report)

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.

Featured Articles

Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.